Comparing Calcium Hydroxylapatite and Hyaluronic Acid for Interdental Papilla Reconstruction

October 27, 2026 updated by: Rusha Alyafi, King Abdulaziz University

Clinical Evaluation of Hyper-Diluted Calcium Hydroxylapatite Versus Hyaluronic Acid in the Reconstruction of Interdental Papilla Deficiencies: A Split-Mouth Study

This study aims to compare two injectable materials, calcium hydroxylapatite (Radiesse®) and hyaluronic acid, for treating gaps between the teeth caused by loss of gum tissue. These gaps, commonly known as "black triangles," can affect the appearance of a person's smile and may cause food to become trapped between the teeth.

Hyaluronic acid has been used to improve the appearance of these gaps, but its effects may not last for a long time. Calcium hydroxylapatite is another injectable material that may help the body produce collagen, a natural protein that supports gum tissue. This study will investigate whether calcium hydroxylapatite can provide better or longer-lasting results compared with hyaluronic acid.

The study will take place at the Faculty of Dentistry, King Abdulaziz University, Jeddah, Saudi Arabia. Approximately 20 healthy adults who have two similar gaps between their front teeth will be invited to participate.

Each participant will receive both treatments. One gap will be treated with diluted calcium hydroxylapatite, while the other will be treated with hyaluronic acid. The treatment for each site will be selected randomly to ensure a fair comparison. Each site will receive one injection.

Participants will be examined before treatment and again after 3 weeks, 3 months, and 6 months to assess the results.

During these visits, photographs and clinical measurements will be taken to evaluate changes in the size of the gaps and the amount of gum tissue between the teeth. Participants will also be asked about their satisfaction with the appearance of their gums, any discomfort experienced during treatment, and whether they have noticed an improvement in their smile. Any side effects or complications will also be recorded.

The researchers will compare how well the two materials improve the appearance of the gaps and how long the improvements last.

Participation will be voluntary, and all participants will receive information about the study before signing a consent form. Their personal information will be kept confidential, and they may withdraw from the study at any time without affecting their dental care.

The main goal of this study is to identify whether diluted calcium hydroxylapatite or hyaluronic acid provides better and longer-lasting improvement in the appearance of gaps between the teeth. The findings may help dentists choose more effective, minimally invasive treatments for patients with missing gum tissue between their teeth.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults aged 18 years or older.
  • Systemically healthy individuals with no history of chronic systemic diseases.
  • Patients with a healthy periodontium.
  • Patients presenting with two comparable interdental papilla deficiencies in the esthetic zone.
  • Patients with Class I interdental papilla loss according to the Nordland and Tarnow classification.

Exclusion Criteria:

  • Patients with chronic systemic diseases.
  • Pregnant or lactating women.
  • Current smokers.
  • Children and adolescents under 18 years of age.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Hyper-Diluted Calcium Hydroxylapatite (Radiesse®)

Interdental papilla deficiencies assigned to this treatment will receive a single injection of hyper-diluted calcium hydroxylapatite (Radiesse®), prepared at a 1:2 dilution ratio using saline and lidocaine. The intervention aims to improve interdental papillary fill and stimulate collagen production, potentially providing longer-lasting tissue improvement. Clinical outcomes will be evaluated at baseline, 3 weeks, 3 months, and 6 months following treatment.

Hyper-diluted calcium hydroxylapatite (Radiesse®) will be used for the treatment of Class I interdental papilla deficiencies. The material will be prepared at a 1:2 dilution ratio using saline and lidocaine, mixed through a Luer-lock syringe connection. Each randomly assigned interdental site will receive a single injection. The treatment aims to stimulate collagen production, improve interdental papillary fill, and enhance soft tissue volume and stability. Clinical outcomes will be evaluated at baseline, 3 weeks, 3 months, and 6 months after treatment.

Hyaluronic acid (HA) injectable filler will be used for the treatment of Class I interdental papilla deficiencies. Each randomly assigned interdental site will receive a single injection of HA to increase soft tissue volume, improve interdental papillary fill, and reduce the appearance of black triangles. Clinical outcomes will be evaluated at baseline, 3 weeks, 3 months, and 6 months after treatment.

Active Comparator: Hyaluronic Acid (HA)

Interdental papilla deficiencies assigned to this treatment will receive a single injection of hyaluronic acid (HA). The intervention aims to improve interdental papillary fill by increasing soft tissue volume and reducing the appearance of black triangles. Clinical outcomes will be evaluated at baseline, 3 weeks, 3 months, and 6 months following treatment.

Hyaluronic acid (HA) injectable filler will be used for the treatment of Class I interdental papilla deficiencies. Each randomly assigned interdental site will receive a single injection of HA to increase soft tissue volume, improve interdental papillary fill, and reduce the appearance of black triangles. Clinical outcomes will be evaluated at baseline, 3 weeks, 3 months, and 6 months after treatment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reduction in Black Triangle Area
Time Frame: Baseline, 3 weeks, 3 months, and 6 months after treatment.

Change in the area of the open gingival embrasure (black triangle) following treatment, measured in square millimeters (mm²) using standardized calibrated digital clinical photographs. The reduction in black triangle area will be compared between the calcium hydroxylapatite and hyaluronic acid treatment sites to evaluate the effectiveness of papillary reconstruction.

Baseline, 3 weeks, 3 months, and 6 months after treatment.
Change in Interdental Papilla Height
Time Frame: Baseline, 3 weeks, 3 months, and 6 months after treatment.

Change in interdental papilla height (mm) from baseline following treatment with hyper-diluted calcium hydroxylapatite or hyaluronic acid. Papillary height will be measured using standardized digital clinical photographs calibrated with a UNC-15 periodontal probe and analyzed using image-analysis software (ImageJ). The distance from the papilla tip to a reference line connecting the adjacent gingival margins will be measured. Changes in papillary height will be compared between the two treatment sites.

Baseline, 3 weeks, 3 months, and 6 months after treatment.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Interdental Papilla Thickness
Time Frame: Baseline, 3 weeks, 3 months, and 6 months after treatment.

Change in interdental papilla thickness (mm) following treatment with calcium hydroxylapatite or hyaluronic acid. Tissue thickness will be assessed using a calibrated endodontic file fitted with a silicone stopper at a standardized reference point. Changes in tissue thickness will be compared between treatment sites to estimate improvements in papillary tissue bulk.

Baseline, 3 weeks, 3 months, and 6 months after treatment.
Patient Satisfaction With Esthetic Outcomes
Time Frame: 3 weeks, 3 months, and 6 months after treatment.

Patient satisfaction with the appearance of the treated interdental papilla will be assessed using a Visual Analog Scale (VAS). Participants will evaluate their satisfaction with the esthetic improvement achieved following each treatment. Satisfaction scores will be compared between the two treatment sites.

3 weeks, 3 months, and 6 months after treatment.
Global Aesthetic Improvement Scale (GAIS)
Time Frame: 3 weeks, 3 months, and 6 months after treatment.

Esthetic improvement will be assessed using the Global Aesthetic Improvement Scale (GAIS), a five-point scale ranging from "worse" to "very much improved." Both participants and investigators will evaluate the improvement in interdental papilla appearance compared with baseline. Scores will be compared between the two treatment sites.

3 weeks, 3 months, and 6 months after treatment.
Stability of Interdental Papillary Fill
Time Frame: 3 weeks, 3 months, and 6 months after treatment.

The stability of interdental papillary reconstruction will be evaluated by comparing changes in papilla height and black triangle dimensions across follow-up visits. The maintenance of treatment-related improvements at 6 months will be assessed to compare the durability of calcium hydroxylapatite and hyaluronic acid injections.

3 weeks, 3 months, and 6 months after treatment.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient Satisfaction Questionnaire (PSQ-18)
Time Frame: 3 weeks, 3 months, and 6 months after treatment.

Patient-reported satisfaction will be evaluated using the Patient Satisfaction Questionnaire Short Form (PSQ-18), consisting of 18 items. The questionnaire will assess satisfaction with treatment, comfort, perceived improvement, and overall treatment experience. Responses will be compared between the two treatment sites.

3 weeks, 3 months, and 6 months after treatment.
Adverse Events and Complications
Time Frame: From the injection procedure through the 6-month follow-up period.

Any adverse effects or complications associated with calcium hydroxylapatite or hyaluronic acid injections will be recorded and compared between the treatment sites. The number and nature of reported complications will be documented to evaluate the safety of both interventions.

From the injection procedure through the 6-month follow-up period.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

July 1, 2028

Study Completion (Estimated)

September 1, 2028

Study Registration Dates

First Submitted

October 27, 2026

First Submitted That Met QC Criteria

October 27, 2026

First Posted (Actual)

November 3, 2026

Study Record Updates

Last Update Posted (Actual)

November 3, 2026

Last Update Submitted That Met QC Criteria

October 27, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 132-09-26

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.